Back to Search
Start Over
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.
- Source :
-
Clinical drug investigation [Clin Drug Investig] 2022 Apr; Vol. 42 (4), pp. 319-331. Date of Electronic Publication: 2022 Mar 15. - Publication Year :
- 2022
-
Abstract
- Background and Objectives: Aclidinium bromide was approved in the European Union for the treatment of chronic obstructive pulmonary disease (COPD) in adult patients in 2012 and in a fixed-dose combination with formoterol in 2014. We characterised new users of aclidinium, aclidinium/formoterol and other COPD medications and evaluated off-label prescribing of these medications in three European populations.<br />Methods: We described demographic characteristics, comorbidities, comedications, COPD severity and off-label prescribing of new users of aclidinium, aclidinium/formoterol and other COPD medications in patients with COPD aged ≥ 40 years in the Clinical Practice Research Datalink (CPRD, UK), Danish National Health Databases, and German Pharmacoepidemiological Research Database (GePaRD) between 2015 and 2017.<br />Results: We included 17,668 new users of aclidinium (CPRD, 4871; Denmark, 2836; GePaRD, 9961) and 14,808 new users of aclidinium/formoterol (CPRD, 2153; Denmark, 2586; GePaRD, 10,069). Study patients were of similar age, except in GePaRD, where users of long-acting beta2-agonists (LABA)/inhaled corticosteroids were younger. Patients had multiple comorbidities and used multiple comedications-most frequently hypertension (50-79%) and short-acting beta2-agonists (26-84%). Aclidinium users in CPRD and long-acting anticholinergics/LABA users in Denmark and GePaRD had the highest frequency of severe/very severe COPD. Off-label prescribing of aclidinium (5.0% [CPRD]-8.9% [Denmark]) and aclidinium/formoterol (2.6% [GePaRD]-3.2% [CPRD]) was low, and the main reason was asthma without a COPD diagnosis.<br />Conclusions: Aclidinium and aclidinium/formoterol were mostly prescribed according to label, with preference given to older patients with more severe COPD and to patients with a high prevalence of comorbidities and comedication use.<br /> (© 2022. The Author(s).)
- Subjects :
- Administration, Inhalation
Adult
Bronchodilator Agents
Denmark
Formoterol Fumarate
Humans
Muscarinic Antagonists therapeutic use
Tropanes adverse effects
Tropanes therapeutic use
United Kingdom epidemiology
Adrenergic beta-2 Receptor Agonists therapeutic use
Pulmonary Disease, Chronic Obstructive diagnosis
Pulmonary Disease, Chronic Obstructive drug therapy
Pulmonary Disease, Chronic Obstructive epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1179-1918
- Volume :
- 42
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinical drug investigation
- Publication Type :
- Academic Journal
- Accession number :
- 35290649
- Full Text :
- https://doi.org/10.1007/s40261-022-01120-2